# Sprout Social, Inc.: financial statements, quarterly

SPT · Nasdaq · CIK 1517375 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/spt.md) · [Financials](/companies/spt/financials.md) · [Filings](/companies/spt/filings.md) · [Insiders](/companies/spt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/spt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [85.5](/filings/0001517375-24-000133.md) | [93.6 d](/filings/0001517375-26-000015.md) | [96.8](/filings/0001517375-25-000083.md) | [99.4](/filings/0001517375-25-000122.md) | [103](/filings/0001517375-25-000142.md) | [107 d](/filings/0001517375-26-000015.md) | [109](/filings/0001517375-26-000038.md) | [112](/filings/0001517375-26-000061.md) | [116](/filings/0001517375-25-000142.md) | [121 d](/filings/0001517375-26-000015.md) | [121](/filings/0001517375-26-000038.md) | [124](/filings/0001517375-26-000061.md) |
| Cost of revenue | $m | [20.2](/filings/0001517375-24-000133.md) | [21.0 d](/filings/0001517375-26-000015.md) | [22.4](/filings/0001517375-25-000083.md) | [22.4](/filings/0001517375-25-000122.md) | [23.2](/filings/0001517375-25-000142.md) | [23.4 d](/filings/0001517375-26-000015.md) | [24.8](/filings/0001517375-26-000038.md) | [24.9](/filings/0001517375-26-000061.md) | [25.8](/filings/0001517375-25-000142.md) | [27.1 d](/filings/0001517375-26-000015.md) | [28.0](/filings/0001517375-26-000038.md) | [27.8](/filings/0001517375-26-000061.md) |
| Gross profit | $m | [65.3](/filings/0001517375-24-000133.md) | [72.6 d](/filings/0001517375-26-000015.md) | [74.4](/filings/0001517375-25-000083.md) | [77.0](/filings/0001517375-25-000122.md) | [79.4](/filings/0001517375-25-000142.md) | [83.7 d](/filings/0001517375-26-000015.md) | [84.5](/filings/0001517375-26-000038.md) | [86.8](/filings/0001517375-26-000061.md) | [89.8](/filings/0001517375-25-000142.md) | [93.7 d](/filings/0001517375-26-000015.md) | [93.5](/filings/0001517375-26-000038.md) | [96.1](/filings/0001517375-26-000061.md) |
| Research and development | $m | [20.1](/filings/0001517375-24-000133.md) | [22.7 d](/filings/0001517375-26-000015.md) | [23.8](/filings/0001517375-25-000083.md) | [25.1](/filings/0001517375-25-000122.md) | [26.3](/filings/0001517375-25-000142.md) | [27.6 d](/filings/0001517375-26-000015.md) | [23.2](/filings/0001517375-26-000038.md) | [24.6](/filings/0001517375-26-000061.md) | [25.1](/filings/0001517375-25-000142.md) | [28.4 d](/filings/0001517375-26-000015.md) | [26.9](/filings/0001517375-26-000038.md) | [26.6](/filings/0001517375-26-000061.md) |
| Operating income | $m | [(24.2)](/filings/0001517375-24-000133.md) | [(18.2) d](/filings/0001517375-26-000015.md) | [(13.3)](/filings/0001517375-25-000083.md) | [(16.5)](/filings/0001517375-25-000122.md) | [(16.9)](/filings/0001517375-25-000142.md) | [(13.7) d](/filings/0001517375-26-000015.md) | [(11.2)](/filings/0001517375-26-000038.md) | [(12.3)](/filings/0001517375-26-000061.md) | [(9.1)](/filings/0001517375-25-000142.md) | [(10.8) d](/filings/0001517375-26-000015.md) | [(5.8)](/filings/0001517375-26-000038.md) | [(2.7)](/filings/0001517375-26-000061.md) |
| Interest expense | $m | [1.1](/filings/0001517375-24-000133.md) | [1.5 d](/filings/0001517375-26-000015.md) | [1.0](/filings/0001517375-25-000083.md) | [1.0](/filings/0001517375-25-000122.md) | [0.9](/filings/0001517375-25-000142.md) | [0.7 d](/filings/0001517375-26-000015.md) | [0.5](/filings/0001517375-26-000038.md) | [0.4](/filings/0001517375-26-000061.md) | [0.8](/filings/0001517375-25-000142.md) | [0.8 d](/filings/0001517375-26-000015.md) | [0.7](/filings/0001517375-26-000038.md) | [0.6](/filings/0001517375-26-000061.md) |
| Income tax | $m | [(1.0)](/filings/0001517375-24-000133.md) | [1.4 d](/filings/0001517375-26-000015.md) | [(0.1)](/filings/0001517375-25-000083.md) | [0.2](/filings/0001517375-25-000122.md) | [0.3](/filings/0001517375-25-000142.md) | [0.3 d](/filings/0001517375-26-000015.md) | [0.2](/filings/0001517375-26-000038.md) | [0.6](/filings/0001517375-26-000061.md) | [0.1](/filings/0001517375-25-000142.md) | [(0.3) d](/filings/0001517375-26-000015.md) | [0.4](/filings/0001517375-26-000038.md) | [0.4](/filings/0001517375-26-000061.md) |
| Net income | $m | [(23.0)](/filings/0001517375-24-000133.md) | [(20.1) d](/filings/0001517375-26-000015.md) | [(13.6)](/filings/0001517375-25-000083.md) | [(16.9)](/filings/0001517375-25-000122.md) | [(17.1)](/filings/0001517375-25-000142.md) | [(14.4) d](/filings/0001517375-26-000015.md) | [(11.2)](/filings/0001517375-26-000038.md) | [(12.0)](/filings/0001517375-26-000061.md) | [(9.4)](/filings/0001517375-25-000142.md) | [(10.7) d](/filings/0001517375-26-000015.md) | [(6.3)](/filings/0001517375-26-000038.md) | [(3.1)](/filings/0001517375-26-000061.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001517375-24-000133.md) | not reported | [(0.24)](/filings/0001517375-25-000083.md) | [(0.30)](/filings/0001517375-25-000122.md) | [(0.30)](/filings/0001517375-25-000142.md) | not reported | [(0.19)](/filings/0001517375-26-000038.md) | [(0.21)](/filings/0001517375-26-000061.md) | [(0.16)](/filings/0001517375-25-000142.md) | not reported | [(0.11)](/filings/0001517375-26-000038.md) | [(0.05)](/filings/0001517375-26-000061.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [41.1](/filings/0001517375-24-000133.md) | [49.8](/filings/0001517375-26-000015.md) | [69.2](/filings/0001517375-25-000083.md) | [80.9](/filings/0001517375-25-000122.md) | [82.9](/filings/0001517375-25-000142.md) | [86.4](/filings/0001517375-26-000015.md) | [101](/filings/0001517375-26-000038.md) | [102](/filings/0001517375-26-000061.md) | [90.6](/filings/0001517375-25-000142.md) | [95.3](/filings/0001517375-26-000061.md) | [112](/filings/0001517375-26-000038.md) | [120](/filings/0001517375-26-000061.md) |
| Current assets | $m | [196](/filings/0001517375-23-000123.md) | [196](/filings/0001517375-25-000022.md) | [178](/filings/0001517375-24-000070.md) | [183](/filings/0001517375-24-000100.md) | [179](/filings/0001517375-24-000133.md) | [210](/filings/0001517375-26-000015.md) | [208](/filings/0001517375-25-000083.md) | [208](/filings/0001517375-25-000122.md) | [195](/filings/0001517375-25-000142.md) | [237](/filings/0001517375-26-000061.md) | [226](/filings/0001517375-26-000038.md) | [242](/filings/0001517375-26-000061.md) |
| Total assets | $m | [400](/filings/0001517375-23-000123.md) | [397](/filings/0001517375-25-000022.md) | [390](/filings/0001517375-24-000070.md) | [394](/filings/0001517375-24-000100.md) | [389](/filings/0001517375-24-000133.md) | [428](/filings/0001517375-26-000015.md) | [425](/filings/0001517375-25-000083.md) | [423](/filings/0001517375-25-000122.md) | [481](/filings/0001517375-25-000142.md) | [523](/filings/0001517375-26-000061.md) | [509](/filings/0001517375-26-000038.md) | [522](/filings/0001517375-26-000061.md) |
| Current liabilities | $m | [163](/filings/0001517375-23-000123.md) | [181](/filings/0001517375-25-000022.md) | [182](/filings/0001517375-24-000070.md) | [187](/filings/0001517375-24-000100.md) | [187](/filings/0001517375-24-000133.md) | [221](/filings/0001517375-26-000015.md) | [214](/filings/0001517375-25-000083.md) | [209](/filings/0001517375-25-000122.md) | [219](/filings/0001517375-25-000142.md) | [256](/filings/0001517375-26-000061.md) | [237](/filings/0001517375-26-000038.md) | [236](/filings/0001517375-26-000061.md) |
| Total liabilities | $m | [255](/filings/0001517375-23-000123.md) | [252](/filings/0001517375-25-000022.md) | [243](/filings/0001517375-24-000070.md) | [241](/filings/0001517375-24-000100.md) | [231](/filings/0001517375-24-000133.md) | [262](/filings/0001517375-26-000015.md) | [249](/filings/0001517375-25-000083.md) | [238](/filings/0001517375-25-000122.md) | [287](/filings/0001517375-25-000142.md) | [320](/filings/0001517375-26-000061.md) | [293](/filings/0001517375-26-000038.md) | [294](/filings/0001517375-26-000061.md) |
| Long-term debt | $m | not reported | [55.0](/filings/0001517375-25-000022.md) | not reported | not reported | not reported | [25.0](/filings/0001517375-26-000015.md) | not reported | not reported | not reported | [40.0](/filings/0001517375-26-000015.md) | not reported | not reported |
| Shareholders' equity | $m | [145](/filings/0001517375-24-000133.md) | [144](/filings/0001517375-26-000015.md) | [147](/filings/0001517375-25-000122.md) | [152](/filings/0001517375-25-000142.md) | [158](/filings/0001517375-25-000142.md) | [167](/filings/0001517375-26-000061.md) | [175](/filings/0001517375-26-000061.md) | [185](/filings/0001517375-26-000061.md) | [194](/filings/0001517375-25-000142.md) | [203](/filings/0001517375-26-000061.md) | [215](/filings/0001517375-26-000061.md) | [229](/filings/0001517375-26-000061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.5) d](/filings/0001517375-24-000133.md) | [(2.6) d](/filings/0001517375-26-000015.md) | [11.2](/filings/0001517375-25-000083.md) | [2.1 d](/filings/0001517375-25-000122.md) | [9.0 d](/filings/0001517375-25-000142.md) | [4.1 d](/filings/0001517375-26-000015.md) | [18.1](/filings/0001517375-26-000038.md) | [5.1 d](/filings/0001517375-26-000061.md) | [9.3 d](/filings/0001517375-25-000142.md) | [10.9 d](/filings/0001517375-26-000015.md) | [25.2](/filings/0001517375-26-000038.md) | [8.5 d](/filings/0001517375-26-000061.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001517375-24-000133.md) | [0.6 d](/filings/0001517375-26-000015.md) | [1.1](/filings/0001517375-25-000083.md) | [0.5 d](/filings/0001517375-25-000122.md) | [0.5 d](/filings/0001517375-25-000142.md) | [0.9 d](/filings/0001517375-26-000015.md) | [1.4](/filings/0001517375-26-000038.md) | [0.9 d](/filings/0001517375-26-000061.md) | [0.8 d](/filings/0001517375-25-000142.md) | [1.1 d](/filings/0001517375-26-000015.md) | [1.1](/filings/0001517375-26-000038.md) | [0.6 d](/filings/0001517375-26-000061.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.7](/filings/0001517375-23-000123.md) | [55.2](/filings/0001517375-24-000070.md) | [55.5](/filings/0001517375-24-000100.md) | [55.8](/filings/0001517375-24-000133.md) | [56.3](/filings/0001517375-25-000083.md) | [56.7](/filings/0001517375-25-000122.md) | [57.2](/filings/0001517375-25-000142.md) | [57.9](/filings/0001517375-26-000038.md) | [58.4](/filings/0001517375-26-000061.md) | [58.9](/filings/0001517375-25-000142.md) | [59.7](/filings/0001517375-26-000038.md) | [60.2](/filings/0001517375-26-000061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.